Hal W. Hirte
Impact in
- Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.5%
- PARP inhibition in cancer therapy
Papers in
- Oncology 46
- HER2/EGFR in Cancer Research 9
- Cancer Treatment and Pharmacology 9
-
- Ovarian cancer diagnosis and treatment 44
- Co-authors
- Amit M. Oza (58 shared papers)Silvia Bacchetti (4 shared papers)Helen Mackay (16 shared papers)Sebastién J. Hotte (28 shared papers)Lillian L. Siu (23 shared papers)Heinz‐Josef Lenz (4 shared papers)Karen A. Gelmon (4 shared papers)Malcolm J. Moore (9 shared papers)
- Journals
- Journal of Clinical Oncology (55 papers)Gynecologic Oncology (12 papers)Annals of Oncology (12 papers)Investigational New Drugs (11 papers)British Journal of Cancer (5 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Hal W. Hirte
155 papers receiving 8.1k citations
Hal W. Hirte's Hit Papers
Peers
Comparison fields: 5 of 123
- Reproductive Medicine 1.8k
- Oncology 3.0k
- Cancer Research 814
- Obstetrics and Gynecology 391
- Pathology and Forensic Medicine 775
Countries citing papers authored by Hal W. Hirte
This map shows the geographic impact of Hal W. Hirte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hal W. Hirte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hal W. Hirte more than expected).
Fields of papers citing papers by Hal W. Hirte
This network shows the impact of papers produced by Hal W. Hirte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hal W. Hirte. The network helps show where Hal W. Hirte may publish in the future.
Co-authors
The 25 scholars most cited alongside Hal W. Hirte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 157 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Hit paper breakdown → | 2011 | 855 |
| 2 | Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG Hit paper breakdown → | 2006 | 543 |
| 3 | Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia Hit paper breakdown → | 2007 | 433 |
| 4 | 2007 | 355 | |
| 5 | Telomerase, Cell Immortality, and Cancer Hit paper breakdown → | 1994 | 343 |
| 6 | Telomerase activity associated with acquisition of malignancy in human colorectal cancer. | 1995 | 319 |
| 7 | 2006 | 260 | |
| 8 | 2006 | 232 | |
| 9 | 2021 | 225 | |
| 10 | 2000 | 215 | |
| 11 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I Hit paper breakdown → | 2021 | 196 |
| 12 | 2007 | 185 | |
| 13 | 2016 | 165 | |
| 14 | 2008 | 163 | |
| 15 | 2008 | 137 | |
| 16 | 2011 | 119 | |
| 17 | 2010 | 119 | |
| 18 | 2006 | 116 | |
| 19 | 2010 | 101 | |
| 20 | 2007 | 99 |
About Hal W. Hirte
Hal W. Hirte is a scholar working on Oncology, Reproductive Medicine, Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research, having authored 157 papers that have together received 8.2k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (44 papers), Renal cell carcinoma treatment (12 papers), HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (9 papers), Glioma Diagnosis and Treatment (8 papers), Cancer, Hypoxia, and Metabolism (7 papers), Cancer Mechanisms and Therapy (6 papers) and Endometrial and Cervical Cancer Treatments (6 papers). The work is most often cited by research in Reproductive Medicine (1.8k citations), Oncology (3.0k citations), Cancer Research (814 citations), Obstetrics and Gynecology (391 citations) and Pathology and Forensic Medicine (775 citations). Hal W. Hirte has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Amit M. Oza, Silvia Bacchetti, Helen Mackay, Sebastién J. Hotte, Lillian L. Siu, Heinz‐Josef Lenz, Karen A. Gelmon, Malcolm J. Moore, Euan Macpherson and Gini F. Fleming. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Annals of Oncology, Investigational New Drugs and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.